Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer
15 févr. 2022 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals to Present at the SVB Leerink Global Healthcare Conference
10 févr. 2022 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
06 janv. 2022 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE
04 janv. 2022 16h05 HE
|
Zynerba Pharmaceuticals, Inc.
– Company plans to focus development of Zygel™ in FXS, ASD and 22q – – Company plans to initiate Phase 3 trial with Zygel in ASD in the second half of 2022 – – Zynerba to hold conference call...
Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium
06 déc. 2021 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™
22 nov. 2021 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights
15 nov. 2021 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
– Initiated RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X Syndrome (FXS); topline results expected second-half 2023 – – Cash runway well into the first half of...
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October
21 oct. 2021 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
19 oct. 2021 16h15 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition
08 oct. 2021 07h30 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...